Latest News
Category: News
Telix today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital (SKGH) in Kamakura,...
Read more
Telix provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4...
Read more
News,
Telix today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit...
Read more
Telix today provides an update to confirm the current status of the ProstACT Global Phase 3 study of its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in...
Read more
News,
Telix today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic products and...
Read more
News,
Telix today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate...
Read more
Join Telix at the 2025 Society of Urologic Oncology (SUO) Annual Meeting, one of the world’s leading international congresses dedicated to advances in urologic cancer care. Telix will be showcasing...
Read more
News,
Telix today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company’s first cyclotron facility in the Asia Pacific region...
Read more
Telix today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] would have undergone a change in clinical management,...
Read more
Telix today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal...
Read more